Zuranolone clinical trials
Also written SAGE-217.
How each study uses zuranolone is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the zuranolone studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 4 Aug 2023 · ZURZUVAE · NDA 217369 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
14 studies that test it; most in 2017 (3)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2017 | 3 |
| 2018 | 2 |
| 2019 | 3 |
| 2020 | 3 |
| 2023 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 13 · Other 1
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test zuranolone.
- Jun 2027Allopregnanolone (Zuranolone) in Post-stroke DepressionPhase 2 · Duke University
Studies
Open first, then newest update. How each study uses zuranolone is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 14
- Allopregnanolone (Zuranolone) in Post-stroke DepressionRecruitingPhase 2Duke UniversityNCT06759558Written as ZuranoloneHow we know
- Zuranolone Pharmacokinetics (PK) and Safety Study Adolescent Participants With Major Depressive Disorder (MDD)CompletedPhase 1BiogenNCT05655507Written as ZuranoloneHow we know
- A Study to Evaluate SAGE-217 in Adult Participants With Major Depressive Disorder (MDD)CompletedPhase 3BiogenNCT03864614Written as SAGE-217How we know
- A Comparative Study of Sage-217 Plus an Antidepressant (ADT) Versus Placebo Plus an ADT in Adults With Major Depressive DisorderCompletedPhase 3BiogenNCT04476030Written as SAGE-217How we know
- A Study to Evaluate the Efficacy of Sage-217 in the Treatment of Adult Participants With Major Depressive Disorder (MDD)CompletedPhase 3BiogenNCT04442490Written as SAGE-217How we know
- A Study to Evaluate SAGE-217 in Participants With Severe Postpartum DepressionCompletedPhase 3BiogenNCT02978326Written as SAGE-217 15/20 mg Oral SolutionHow we know
- A Study to Evaluate SAGE-217 in Participants With Bipolar I/II Disorder With a Current Major Depressive EpisodeCompletedPhase 2BiogenNCT03692910Written as SAGE-217How we know
- A Study to Evaluate the Efficacy and Safety of SAGE-217 in Participants With Severe Postpartum Depression (PPD)CompletedPhase 3BiogenNCT04442503Written as SAGE-217How we know
- A Study to Assess the Pharmacodynamic Effects of SAGE-217 in Healthy Adults Using an Insomnia ModelCompletedPhase 1BiogenNCT03284931Written as SAGE-217 high doseHow we know
- A Study to Evaluate the Efficacy of SAGE-217 in the Treatment of Adult Participants With Major Depressive DisorderCompletedPhase 3BiogenNCT03672175Written as SAGE-217How we know
- A Study to Evaluate SAGE-217 for Prevention of Relapse in Adult Participants With Major Depressive DisorderTerminatedPhase 3BiogenNCT04007367Written as SAGE-217How we know
- A Study to Evaluate the Safety, Tolerability, and Efficacy of SAGE-217 Compared to Placebo in Adult Participants With Comorbid Major Depressive Disorder (MDD) and InsomniaTerminatedPhase 3BiogenNCT03771664Written as SAGE-217How we know
- A Study to Evaluate SAGE-217 in Participants With Moderate to Severe Major Depressive DisorderCompletedPhase 2BiogenNCT03000530Written as SAGE-217How we know
- A Study to Evaluate SAGE-217 in Participants With Essential TremorCompletedPhase 2BiogenNCT02978781Written as SAGE-217How we know
Given beside what is tested · 1 — zuranolone is usual care or a partner of the new treatment
Codes
What other systems call zuranolone · ClinicalTrials.gg INT001175
- MeSH (NLM) C000634505zuranoloneConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 7ZW49N180BZURANOLONEConfirmed FDA, NLM, Wikidata
- Wikidata Q48862264zuranoloneConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C171709ZuranoloneOne source FDA
- DrugBank DB15490One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000634505 | zuranolone | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 7ZW49N180B | ZURANOLONE | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q48862264 | zuranolone | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C171709 | Zuranolone | One source FDA |
| DrugBank | DB15490 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.